PEDFIC 1 is a Phase 3 clinical trial of investigational product candidate odevixibat, an ileal bile acid transporter (IBAT) inhibitor. To learn more about participating in the PEDFIC clinical trial, please complete the form below.
Odevixibat is being studied as a treatment for children with progressive familial intrahepatic cholestasis (PFIC) 1 or 2. The study is assessing change in pruritus, or severe itching, as well as change in serum bile acids. Sites are recruiting globally and locations may be found on the study page on ClinicalTrials.gov (NCT03566238).
Albireo Pharma, the study’s sponsor, is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders.
If you are a caregiver or a healthcare provider and would like to learn more about the PEDFIC 1 study, just complete the form below.